Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“How safe is the combination of radiotherapy and targeted therapy? Insights from the ESMO–ESTRO consensus
The newly published consensus highlights potential toxicity risks when combining radiotherapy with EGFR, ALK, and BRAF/MEK inhibitors, and provides practical guidance for clinical practice.
Key messages:
- In many scenarios, RT + targeted therapy may increase toxicity
- Therefore, temporary drug interruption, dose modification, or RT adaptation (major adaptation) is often recommended
Quick clinical takeaways:
- EGFR inhibitors + most high-dose RT: Consider major adaptation
- Osimertinib + high-dose thoracic RT: Avoid concurrent use
- ALK inhibitors + most RT scenarios: Major adaptation recommended
- BRAF/MEK inhibitors + most RT: Major adaptation often required
- BRAF inhibitors + high-dose skin RT: Avoid concurrent use
- Vemurafenib + skin RT: Avoid even with low-dose palliative RT
- Low-dose palliative bone/skin RT: May allow a more flexible approach
Bottom line: As targeted therapies continue to expand, safely integrating systemic precision treatments with local therapies remains a key challenge in modern oncology.”
Title: ESMO-ESTRO consensus statements on the safety of combining radiotherapy with EGFR, ALK, or BRAF/MEK inhibitors
Authors: E.S.M. van Aken, S.M. O’Cathail, A.K. Gandhi, J. Bussink, L. Castelo-Branco, J.G. Eriksen, G. Argilés, C.T. Hiley, V. Atkinson, J. Kaźmierska, A. Calles, K. Konopa, E. Le Rhun, F. McDonald, G. Mountzios, P.M. Putora, B. Muoio, U. Ricardi, C.B. Westphalen, A. Wrona, P. Boot, G. Pentheroudakis, C. Belka, F. Lordick, C.A.M. Marijnen, D. Martins-Branco, D. De Ruysscher, J. Barriuso, B. Devnani, M.C. de Jong, A. Prelaj
Read the Full Article.
Other OncoDaily articles featuring Prof. Ahmet Dirican.